论文部分内容阅读
目的观察重组人血小板生成素(rh PO)在白血病化疗后血小板(PLT)减少症患者中的临床治疗价值。方法选择白血病化疗后PLT减少症患者100例,采用随机数字法分成观察组和对照组各50例,观察组给予rhTPO治疗,对照组给予重组人白介素-11(rhiL-11)治疗。对比2组患者的疗效及不良反应发生情况。结果治疗后观察组最大PLT水平明显高于对照组(P<0.05),PLT<50×10~9/L持续时间、PLT恢复到75×10~9/L及100×10~9/L的时间短于对照组(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。结论 rhTPO在白血病化疗后PLT减少症患者的治疗中可获良好的疗效,且不良反应较少,值得临床借鉴。
Objective To investigate the clinical value of recombinant human thrombopoietin (rh PO) in the treatment of patients with leukemia after thrombocytopenia (PLT). Methods One hundred patients with PLT reduction after leukemia chemotherapy were selected and randomly divided into observation group and control group with 50 cases in each group. The observation group was treated with rhTPO, while the control group was treated with recombinant human interleukin-11 (rhiL-11). The efficacy and adverse reactions of two groups were compared. Results After treatment, the maximum PLT level in the observation group was significantly higher than that in the control group (P <0.05). The duration of PLT <50 × 10 ~ 9 / L and PLT recovery to 75 × 10 ~ 9 / L and 100 × 10 ~ 9 / L Time was shorter than that of the control group (P <0.05). The incidence of adverse reactions in the observation group was lower than that of the control group (P <0.05). Conclusions rhTPO has good curative effect in the treatment of patients with PLT reduction after leukemia chemotherapy with less adverse reactions, which is worthy of clinical reference.